期刊文献+

骨髓CD34^+细胞体外扩增诱导树突状细胞实验研究 被引量:2

Expansion of dendritic cells from human bone marrow CD34^+ progenitor cells
下载PDF
导出
摘要 目的探讨应用不同细胞因子组合方案从骨髓CD34+细胞体外扩增诱导树突状细胞(DC)的可行性及评价不同诱导方案诱导DC的效果。方法免疫磁珠法纯化骨髓CD34+细胞。在有血清条件下应用两步法:SCF+FL+TPO+IL-3扩增2周,然后以GM-CSF+IL-4+TNF-α(GI方案)或GM-CSF+TNF-α(GT方案)诱导DC;或者一步法:SCF+FL+TPO+IL-3+GM-CSF+TNF-α直接作用2周扩增诱导DC。通过相差显微镜、电子显微镜、流式细胞仪分析、异硫氰酸荧光素标记的葡聚糖(FITC-DX)内吞实验检测DC的生物学特性。结果诱导后细胞较0d或诱导前细胞高表达DC相关标记(CD1a、CD80、CD86、CD40、CD54、HLA-DR)。两步法GI方案诱导10d,总细胞扩增倍数、CD1a+DC扩增倍数分别为(198±178)倍和(122±129)倍,与GT方案比较无统计学意义,但诱导细胞CD1a、CD80、CD86的表达明显高于后者。一步法扩增诱导2周时总细胞数扩增(43±16)倍,CD1a+DC数是0d接种细胞的(4±2)倍。结论两步法能从正常CD34+细胞诱导产生大量DC,GI方案优于GT方案。两者扩增效率均优于一步法。 Objective To study the ex vivo expansion efficiency of dendritic cells (DCs) from human bone marrow CD34+ progenitor cells and this biological properties. Methods CD34+ cells were purified by using CD34 microbeads from normal bone marrow and cultured in serum-dependent medium by two ways:①Two-step culture method,expension in the presence of stem cell factor(SCF),Flt-3 ligand(FL),thrombopoietin(TPO) and interleukin-3(IL-3) for 14 days,and then cultured with granulocyte-macrophage colony stimulating factor(GM-CSF) and interleukin-4(IL-4) for 7 days in addition to tumor necrosis factor-α (TNF-α) for another 3 ~ 4 days (group GI),or with GM-CSF plus TNF-a for 10 or more days (group GT);②One-step culture method,cultured in SCF,FL,TPO,IL-3,GM-CSF and TNF-α for 14 days. The biological properties of DCs were examined by phase contrast microscope,electron microscope,flow cytometry and fluorescein isothiocyanate conjugated dextran (FITC-DX) uptake test. Results These cells showed a typical dendritic phenotype:they were highly positive for DC marker CD1a,costimulatory molecule CD80,CD86,CD40,adhesion molecule CD54, and HLA-DR and negative for CD3 and CD19. After inducing for 10 days in group GI,the number of total cell and CD1a+ DCs generated increasingly (198±178) fold and (122±129) fold,respectively. Comparing with group GT,group GI produced a similar total cell number and CD1a+DCs number, but induced a higher expression of CD1a,CD80 and CD86. The number of total cell and CD1a+ DCs generated increasingly (43±16) fold and (4±2) fold,respectively. Conclusions A large number of DCs could be induced from normal CD34+ cells in a two-step process. The GI scheme is superior to GT scheme on the quality of DCs and both are superior to one-step culture method.
出处 《生物医学工程与临床》 CAS 2005年第4期227-231,F002,共6页 Biomedical Engineering and Clinical Medicine
基金 人事部留学回国人员启动基金资助
关键词 树突状细胞 CD34^+细胞 体外扩增 dendritic cells CD34+ cells ex vivo expansions
  • 相关文献

参考文献9

  • 1Banchereau J, Steinman RM. Dendritic cells and the control of immunity [J]. Nature, 1998,392(6673): 245-252.
  • 2Hart DNJ. Dendritic cells: unique leukocyte populations which control the primary immune response [J]. Blood, 1997,90(9):3245-3287.
  • 3Arrighi JF,Hauser C ,Chapuis B,et al. Long-term culture of human CD34+ progenitors with FLT3-ligand,thrombopoietin,and stem cell factor induces extensive amplification of a CD34-CD14- and a CD34-CD14+ dendritic cell precursor [J]. Blood,1999,93(7): 2244-2252.
  • 4Rosenzwajg M,Canque B,Gluckman JC. Human dendritic cell differentiation pathway from CD34 + hematopoietic precursor cells [J]. Blood, 1996,87(2): 535-544.
  • 5Rosenzwajg M,Camus S,Guigon M,et al. The influence of interleukin (IL)-4,IL-13 ,and FLT3 ligand on human dendritic cell differentiation from cord blood CD34+ progenitor cells [J].Exp Hematol, 1998,26(1):63-72.
  • 6Banchereau J, Schuler-Thumer B, Palucka AK, et al. Dendritic cells as vectors for therapy [J]. Cell,2001,106(3) :271-274.
  • 7Szabdcs P, Moore MAS, Young JW. Expansion of immunostimulatory dendritic cell among the myeloid progency of human CD34 + bone marrow precursors cultured with c-kit ligand,granulocyte-macrophage colony-stimulating factor,and TNFα[J]. J I mmunol, 1995,154( 11 ): 5851-5861.
  • 8Bykovskaia SN, Shurin GV ,Graner S ,et al. Differentiation of immunostimulatory stem-cell- and monocyte-derived dendritic cells involves maturation of intracellular compartments responsible for antigen presentation and secretion [J]. Stem Cells,2002,20(5):380-393.
  • 9Schwartz RH. Immunology. It takes more than two to tango [J].Nature, 2001,409(6816):31-32.

同被引文献16

  • 1彭正,李荣,李力,张磊,金婷.自体树突状细胞体外增强肿瘤患者引流淋巴结细胞抗肿瘤活性的作用[J].细胞与分子免疫学杂志,2004,20(5):595-597. 被引量:10
  • 2罗道升,戴宇平.树突状细胞相关基础研究进展[J].国外医学(免疫学分册),2005,28(1):51-55. 被引量:18
  • 3董子明.肿瘤疫苗和肿瘤的免疫治疗[J].河南大学学报(医学科学版),2004,23(4):1-8. 被引量:1
  • 4Eugene MK,Muthukumaran S,Christos IS,et al.Adjuvant effect of a flt-3 ligand (FL) gene-transduced Xenogeneic cell line in a murine colon cancer model[J].J Surg Res,2002,108 (1):148-156.
  • 5Di-Nicola M,Carlo-Stella C,Magni M,et al.Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli[J].Blood,2002,99:3838-3843.
  • 6O'Neill DW,Adams S,Bhardwaj N.Manipulating dendritic cell biology for the active immunotherapy of cancer[J].Blood,2004,104(8):2235-2246.
  • 7Brossart P,Wirths S,Brugger W,et al.Dendritic cells in cancer vaccines[J].Exp Hematol,2001,29(11):1247-1255.
  • 8Lee SJ.Chronic myelogenous leukaemia[J].Br J Haematol,2000,111(4):993-1009.
  • 9Choudhury A,Gajewski JL,Liang JC,et al.Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against philadelphia chmmosome-positive chronic myelogenous leukemia[J].Blood,1997,89(4):1133-1142.
  • 10Fujii S,Shimizu K,Fujimoto K,et al.Analysis ofa chronic myelogenous leukemia patient vaccinated witIl leukemic dendritic cells following autologous peripheral blood stem cell transplantation[J].Jpn J Cancer Res,1999,90(10):1117-1129.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部